Post-earnings recap
Reported
Thu, Jul 30, 2026
EPS actual
$-1.54
EPS est.
$-1.58
EPS surprise
+2.78%
1-day move
+7.52%
Disc Medicine, Inc. reported a smaller loss than analysts expected, which contributed to a positive stock reaction, with shares rising by 7.52%. The lack of revenue and guidance indicates that the company is still in a development phase. Investors may view the EPS beat as a sign of potential improvement in future quarters.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.54 | $-1.74 | +2.78% |
| Revenue | $0M | $0M | — |
No transcript is on record, so the analysis is based solely on numerical results.
Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders. Operating in the health care sector, its work is crucial as it addresses unmet medical needs in a specialized area of medicine.
Last quarter
In Q1-2026, Disc Medicine reported an EPS of -1.65, which was a miss compared to the estimate of -1.55. The stock saw a slight decline of 0.07% the following day.
EPS beat streak
1Q
EPS beat rate
38%
Avg EPS surprise
-38.41%
Avg 1-day reaction
+0.67%
Analysts are expecting another loss for Disc Medicine this quarter, with a consensus EPS of -1.74. Investors will be watching closely for any signs of progress in their drug development pipeline.
Bull case
If the company can demonstrate advancements in its clinical trials or provide positive updates on its product pipeline, it could lead to increased investor confidence and a potential stock rally.
Bear case
Conversely, if the company reports a larger-than-expected loss or fails to provide any positive updates, it could lead to further declines in stock price and investor sentiment.
Key metrics to watch
EPS
-1.74Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.
Revenue
0MWhile no revenue is expected this quarter, any updates on future revenue prospects will be important for investor confidence.
The print will turn on these.
Q1
What specific updates can management provide on the progress of their clinical trials?
Investors will be keen to understand if there are any advancements or setbacks in the drug development process, which could significantly impact future revenue potential.
Q2
Will there be any guidance on expected timelines for product launches?
Clear timelines can help set investor expectations and influence stock performance based on perceived future growth.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±7.0%
Why consensus could be wrong
The Street may be underestimating the potential for positive updates on clinical trials, which could lead to a more favorable outlook than currently anticipated.
Supporting evidence
The options market is pricing a 22.14% move, indicating expectations of significant volatility that may not align with historical performance.
The company has a history of surprising investors with better-than-expected trial results, which could lead to a positive shift in sentiment.
Key risk
If clinical trial updates indicate faster progress than expected, it could challenge the current consensus view.
Pre-commit to what would confirm each case.
This quarter's focus is on whether the company can show progress in its drug development efforts while managing costs effectively.
Bull confirmed if
A reduction in EPS loss to -1.50 or better, coupled with positive updates on clinical trials, would confirm the bull case.
Bear confirmed if
An EPS loss greater than -2.00 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±22.14%
Historical Avg
±3.1%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings report.
Options are pricing ±22.1% while IRON has averaged ±3.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
32.9%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
114.11%
of float
Insider
7.84%
of float
Holders
303
institutions
Top Holders· as of Jun 2026
FMR, LLC
4,894,473 sh · $299.4M
12.75%
-12.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Disc Medicine beats expectations and raises guidance, history suggests a potential stock increase of around 0.64% on the following day.
In line / cautious
If results are in line with expectations, management's commentary will be crucial and could lead to a muted reaction.
Miss
Should the company miss expectations, history suggests a potential decline of about 0.64% on the following day.
The lines on the call that would change the story.
Blackrock Inc.
2,467,899 sh · $151.0M
6.43%
8.5%
RA Capital Management, L.P.
2,450,221 sh · $149.9M
6.38%
Flat
JPMORGAN CHASE & CO
1,875,795 sh · $114.8M
4.89%
36.8%
Price (T.Rowe) Associates Inc
1,875,399 sh · $114.7M
4.88%
21.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.